Passage Bio Inc. (PASG) News
Filter PASG News Items
PASG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PASG News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PASG News From Around the Web
Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business UpdatesPBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial de |
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Passage Bio assumed with an Outperform at WedbushWedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage’s upsized IPO, but the current valuation looks to be a “deep discount” compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors. Published first on The |
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating(Updated to include Wedbush's commentary) Wedbush has increased its price target for Passage Bio |
Passage Bio Achieves Milestones in Gene Therapy TrialsPassage Bio ( (PASG) ) has issued an update. Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This |
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsEnrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by stro |
Passage Bio to Present at Guggenheim Securities Healthcare Innovation ConferencePHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s websi |
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual ConferencePreclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates Company delivered data during an oral presentation on Thursday, October 24 at ESGCT PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- P |
Orbimed Advisors LLC Adjusts Stake in Passage Bio IncOn September 19, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction involving the shares of Passage Bio Inc (NASDAQ:PASG). Despite this reduction, Orbimed Advisors LLC maintains a substantial position in Passage Bio, holding 12.62% of the company's shares, which represents 0.11% of their total portfolio. Founded in 1989, Orbimed Advisors LLC has grown into a global leader in healthcare investment, managing approximately $15 billion across various funds. |
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines ConferencePHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at inv |